DOP2011000127A - Derivados de pirrolidina para usar como antagonistas del receptor de progesterona - Google Patents
Derivados de pirrolidina para usar como antagonistas del receptor de progesteronaInfo
- Publication number
- DOP2011000127A DOP2011000127A DO2011000127A DO2011000127A DOP2011000127A DO P2011000127 A DOP2011000127 A DO P2011000127A DO 2011000127 A DO2011000127 A DO 2011000127A DO 2011000127 A DO2011000127 A DO 2011000127A DO P2011000127 A DOP2011000127 A DO P2011000127A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- derivatives
- formula
- preparation
- pelvic pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La invención se refiere a una clase de compuestos de pirrolidina de fórmula (l), y sus derivados farmacéuticamente aceptables, a su uso en medicina, a composiciones que los contienen, y a procesos para su preparación. También se refiere a intermedios utilizados en la preparación de dichos compuestos y derivados. En particular, los compuestos de fórmula (l) son útiles para el tratamiento de trastornos mediados por EP2, como la endometriosis, los fibroides uterinos (leiomiomata), la menorragia, la adenomiosis, la dismenorrea primaria y secundaria (incluyendo los síntomas de dispareunia, disquexia y dolor pélvico crónico), el síndrome del dolor pélvico crónico, la enfermedad del riñón poliquístico y el síndrome del ovario poliquístico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11286908P | 2008-11-10 | 2008-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2011000127A true DOP2011000127A (es) | 2011-07-15 |
Family
ID=41503565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2011000127A DOP2011000127A (es) | 2008-11-10 | 2011-05-06 | Derivados de pirrolidina para usar como antagonistas del receptor de progesterona |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8278343B2 (es) |
| EP (1) | EP2364296A1 (es) |
| JP (1) | JP2012508225A (es) |
| KR (1) | KR20110083733A (es) |
| CN (1) | CN102209710A (es) |
| AP (1) | AP2011005728A0 (es) |
| AR (1) | AR074314A1 (es) |
| AU (1) | AU2009312427B2 (es) |
| BR (1) | BRPI0920924A2 (es) |
| CA (1) | CA2741589A1 (es) |
| CL (1) | CL2011001034A1 (es) |
| CO (1) | CO6382112A2 (es) |
| CR (1) | CR20110217A (es) |
| CU (1) | CU20110093A7 (es) |
| DO (1) | DOP2011000127A (es) |
| EA (1) | EA201100549A1 (es) |
| EC (1) | ECSP11011032A (es) |
| GE (1) | GEP20125607B (es) |
| IL (1) | IL212490A0 (es) |
| MA (1) | MA32782B1 (es) |
| MX (1) | MX2011004903A (es) |
| NI (1) | NI201100092A (es) |
| NZ (1) | NZ592311A (es) |
| PA (1) | PA8848001A1 (es) |
| PE (1) | PE20110663A1 (es) |
| SV (1) | SV2011003896A (es) |
| TN (1) | TN2011000211A1 (es) |
| TW (1) | TW201022234A (es) |
| UY (1) | UY32228A (es) |
| WO (1) | WO2010052625A1 (es) |
| ZA (1) | ZA201104310B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| WO2013176220A1 (ja) * | 2012-05-25 | 2013-11-28 | 国立大学法人京都大学 | 概日リズム調整 |
| CN110041269A (zh) * | 2019-05-16 | 2019-07-23 | 海门瑞一医药科技有限公司 | 一种2-氯-5-羟基嘧啶的制备方法 |
| WO2022272062A1 (en) * | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5319099A (en) * | 1991-01-21 | 1994-06-07 | Shionogi Seiyaku Kabushiki Kaisha | 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents |
| US7335680B2 (en) * | 2001-12-20 | 2008-02-26 | Laboratoires Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
| WO2007005176A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
| DE102006039912A1 (de) * | 2006-08-25 | 2008-03-20 | Bayer Healthcare Ag | Substituierte Spirotetronsäuren und ihre Verwendung |
| KR20100009582A (ko) * | 2007-05-10 | 2010-01-27 | 화이자 리미티드 | 아제티딘 유도체 및 프로스타글란딘 ｅ2 길항제로서 그의 용도 |
-
2009
- 2009-10-30 GE GEAP200912219A patent/GEP20125607B/en unknown
- 2009-10-30 EP EP09756838A patent/EP2364296A1/en not_active Withdrawn
- 2009-10-30 KR KR1020117013231A patent/KR20110083733A/ko active IP Right Grant
- 2009-10-30 CN CN2009801446055A patent/CN102209710A/zh active Pending
- 2009-10-30 BR BRPI0920924A patent/BRPI0920924A2/pt not_active IP Right Cessation
- 2009-10-30 AP AP2011005728A patent/AP2011005728A0/xx unknown
- 2009-10-30 PE PE2011001004A patent/PE20110663A1/es not_active Application Discontinuation
- 2009-10-30 AU AU2009312427A patent/AU2009312427B2/en not_active Ceased
- 2009-10-30 JP JP2011535189A patent/JP2012508225A/ja not_active Ceased
- 2009-10-30 WO PCT/IB2009/054824 patent/WO2010052625A1/en active Application Filing
- 2009-10-30 MX MX2011004903A patent/MX2011004903A/es active IP Right Grant
- 2009-10-30 EA EA201100549A patent/EA201100549A1/ru unknown
- 2009-10-30 CA CA2741589A patent/CA2741589A1/en not_active Abandoned
- 2009-10-30 NZ NZ592311A patent/NZ592311A/xx not_active IP Right Cessation
- 2009-11-06 US US12/613,771 patent/US8278343B2/en not_active Expired - Fee Related
- 2009-11-09 UY UY0001032228A patent/UY32228A/es not_active Application Discontinuation
- 2009-11-09 PA PA20098848001A patent/PA8848001A1/es unknown
- 2009-11-09 TW TW098137955A patent/TW201022234A/zh unknown
- 2009-11-10 AR ARP090104350A patent/AR074314A1/es not_active Application Discontinuation
-
2011
- 2011-04-25 CU CU20110093A patent/CU20110093A7/es unknown
- 2011-04-26 CR CR20110217A patent/CR20110217A/es unknown
- 2011-04-26 IL IL212490A patent/IL212490A0/en unknown
- 2011-04-29 TN TN2011000211A patent/TN2011000211A1/fr unknown
- 2011-05-05 EC EC2011011032A patent/ECSP11011032A/es unknown
- 2011-05-06 DO DO2011000127A patent/DOP2011000127A/es unknown
- 2011-05-06 SV SV2011003896A patent/SV2011003896A/es unknown
- 2011-05-09 NI NI201100092A patent/NI201100092A/es unknown
- 2011-05-09 CL CL2011001034A patent/CL2011001034A1/es unknown
- 2011-05-10 MA MA33829A patent/MA32782B1/fr unknown
- 2011-05-11 CO CO11058068A patent/CO6382112A2/es not_active Application Discontinuation
- 2011-06-09 ZA ZA2011/04310A patent/ZA201104310B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2011005728A0 (en) | 2011-06-30 |
| CA2741589A1 (en) | 2010-05-14 |
| MA32782B1 (fr) | 2011-11-01 |
| WO2010052625A1 (en) | 2010-05-14 |
| AU2009312427A1 (en) | 2010-05-14 |
| ZA201104310B (en) | 2012-02-29 |
| IL212490A0 (en) | 2011-06-30 |
| SV2011003896A (es) | 2011-07-05 |
| ECSP11011032A (es) | 2011-06-30 |
| AU2009312427B2 (en) | 2011-10-20 |
| KR20110083733A (ko) | 2011-07-20 |
| TN2011000211A1 (fr) | 2012-12-17 |
| PE20110663A1 (es) | 2011-09-23 |
| TW201022234A (en) | 2010-06-16 |
| EA201100549A1 (ru) | 2011-12-30 |
| CL2011001034A1 (es) | 2011-11-11 |
| US20100120793A1 (en) | 2010-05-13 |
| EP2364296A1 (en) | 2011-09-14 |
| CO6382112A2 (es) | 2012-02-15 |
| GEP20125607B (en) | 2012-08-10 |
| NZ592311A (en) | 2012-12-21 |
| NI201100092A (es) | 2011-10-31 |
| PA8848001A1 (es) | 2010-06-28 |
| BRPI0920924A2 (pt) | 2016-10-04 |
| CN102209710A (zh) | 2011-10-05 |
| JP2012508225A (ja) | 2012-04-05 |
| AR074314A1 (es) | 2011-01-05 |
| CU20110093A7 (es) | 2012-01-31 |
| US8278343B2 (en) | 2012-10-02 |
| UY32228A (es) | 2010-06-30 |
| MX2011004903A (es) | 2011-05-30 |
| CR20110217A (es) | 2011-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000127A (es) | Derivados de pirrolidina para usar como antagonistas del receptor de progesterona | |
| CY1119661T1 (el) | 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγα, μεθοδοι για την παραγωγη αυτων και χρηση αυτων για την αγωγη παθησεων | |
| CL2008003591A1 (es) | Compuestos derivados de isoxazolo-piridina sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de trastornos cognitivos y alzheimer, mediado por la union al sitio de fijacion del receptor gaba a alfa 5. | |
| UY29904A1 (es) | Compuestos útiles en terapia | |
| PA8827901A1 (es) | Derivados de quinoxalin- y quinolin-carboxamida | |
| CR10922A (es) | Derivados de indol como antagonistas receptores de s1p1 | |
| CL2009000368A1 (es) | 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. | |
| ECSP055762A (es) | 4-amino-1-(piridilmetil)piperidina sustituida como antagonistas de receptores muscarinicos | |
| AR068509A1 (es) | Antagosnistas del receptor de bradiquinina b1 | |
| DOP2009000256A (es) | Derivados de azetidina y su uso como antagonistas de prostaglandina e2 | |
| ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
| AR062114A1 (es) | Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos. | |
| CO6531479A2 (es) | Derivados de espirolactama y uso de los mismos | |
| ECSP078043A (es) | Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona | |
| CO6690116A1 (es) | Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen | |
| UY29625A1 (es) | Uso de moduladores no esteroides de receptores de progesterona | |
| ATE525360T1 (de) | Neuartige imidazolinylmethyl-aryl-sulfonamide | |
| PH12015502326A1 (en) | Progesterone receptor antagonist dosage form | |
| ECSP11010780A (es) | Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a | |
| CR9598A (es) | Moduladores no esteroides de receptor de progesterona | |
| EA201290532A1 (ru) | Бициклические тиазолы в качестве аллостерических модуляторов рецепторов mglur5 | |
| CL2017002969A1 (es) | Derivados de etinilo | |
| CO6331339A2 (es) | Derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
| UY30815A1 (es) | Moduladores no esteroidales del receptor de progesterona | |
| UY30805A1 (es) | Moduladores no esteroides de receptores de progesterona |